| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
17,070,000 |
| Market
Cap: |
92.01(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.39 - $5.39 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company. Co. is developing a modular peptide-nucleic acid antisense oligo (PATrOL™) platform to address genetic diseases. Co.'s programs are: NT0100, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the Huntington's disease messenger ribonucleic acid; NT0200, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the myotonic dystrophy type 1 disease messenger ribonucleic acid; and NT-0300, which is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
61,076 |
61,076 |
| Total Buy Value |
$0 |
$0 |
$59,732 |
$59,732 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
489,520 |
489,520 |
| Total Sell Value |
$0 |
$0 |
$712,352 |
$712,352 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
6 |
6 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Slakter Jason Scott |
Chief Executive Officer |
• • – |
2016-03-07 |
4 |
B |
$3.41 |
$22,669 |
D/D |
6,250 |
878,254 |
2.81 |
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2016-02-22 |
4 |
B |
$3.06 |
$19,432 |
D/D |
6,250 |
872,004 |
2.81 |
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2016-01-19 |
4 |
B |
$3.52 |
$22,606 |
D/D |
6,250 |
865,754 |
2.81 |
- |
|
| Backenroth Samuel |
Chief Financial Officer |
• – – |
2016-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
130,000 |
136,199 |
|
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2016-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
350,358 |
859,504 |
|
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2015-12-15 |
4 |
A |
$0.00 |
$0 |
I/I |
497,859 |
697,865 |
|
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2015-12-07 |
4 |
AB |
$4.00 |
$12,219 |
D/D |
3,000 |
509,146 |
|
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2015-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
428,223 |
506,146 |
|
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2015-11-03 |
4 |
B |
$3.01 |
$301 |
D/D |
100 |
77,923 |
2.73 |
- |
|
| Slakter Jason Scott |
Chief Executive Officer |
• • – |
2015-11-02 |
4 |
B |
$2.97 |
$39,738 |
D/D |
13,250 |
77,823 |
2.81 |
- |
|
| Ingerman Avner |
Chief Clinical OfficerOfficer |
• – – |
2015-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
- |
|
| Backenroth Samuel |
Chief Financial Officer |
• – – |
2015-02-06 |
4 |
B |
$6.75 |
$10,125 |
D/D |
1,500 |
6,199 |
2.74 |
- |
|
| Almenoff June Sherie |
Director |
– • – |
2015-02-06 |
4 |
B |
$6.75 |
$40,500 |
D/D |
6,000 |
16,900 |
2.39 |
- |
|
| Slakter Jason Scott |
Director |
– • – |
2015-02-06 |
4 |
B |
$6.75 |
$200,003 |
D/D |
29,630 |
64,573 |
2.39 |
- |
|
| Taraporewala Irach B. |
Chief Executive Officer |
• • – |
2015-02-06 |
4 |
B |
$6.75 |
$25,009 |
D/D |
3,705 |
22,800 |
2.81 |
- |
|
| Greenstein Ira A |
Director |
– • – |
2015-01-15 |
4 |
OE |
$1.65 |
$90,187 |
D/D |
54,659 |
431,051 |
|
- |
|
| Slakter Jason Scott |
Director |
– • – |
2015-01-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
34,943 |
|
- |
|
| Slakter Jason Scott |
Director |
– • – |
2015-01-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
425,505 |
|
- |
|
| Hirschman Orin |
Director |
– • • |
2014-09-08 |
4 |
OE |
$6.75 |
$485,244 |
I/I |
71,888 |
1,750,748 |
|
- |
|
| Greenstein Ira A |
Director |
– • – |
2014-09-08 |
4 |
OE |
$6.75 |
$41,330 |
D/D |
6,123 |
443,059 |
|
- |
|
| Almenoff June Sherie |
Director |
– • – |
2014-09-03 |
4 |
B |
$8.05 |
$9,660 |
D/D |
1,200 |
127,566 |
2.39 |
- |
|
| Almenoff June Sherie |
Director |
– • – |
2014-09-02 |
4 |
B |
$8.12 |
$8,120 |
D/D |
1,000 |
126,366 |
2.39 |
- |
|
| Greenstein Ira A |
Director |
– • – |
2014-07-02 |
4 |
B |
$8.40 |
$8,400 |
D/D |
1,000 |
456,496 |
2.39 |
- |
|
| Almenoff June Sherie |
Director |
– • – |
2014-06-26 |
4 |
B |
$8.34 |
$26,688 |
D/D |
3,200 |
125,366 |
2.39 |
- |
|
| Riedhammer Thomas M |
Director |
– • – |
2014-06-25 |
4 |
B |
$7.39 |
$50,991 |
D/D |
6,900 |
124,667 |
2.39 |
- |
|
84 Records found
|
|
Page 3 of 4 |
|
|
